Search PubMed⌕ Search

Biomedical subjects

L Heilbrun

Publications and source records attributed to L Heilbrun.

21 records · Page 2Linked to original sources
PubMed1978

5FU infusion with mitomycin-C versus 5 FU infusion with methyl-CCNU in the treatment of advanced colon cancer: a Southwest Oncology Group Study.

The Southwest Oncology Group (SWOG) in a randomized trial evaluated 5FU infusions in combination with either Mitomycin-C or Methyl-CCNU in patients with disseminated large bowel cancer. A response rate of 18% was noted on the 5FU-Mitomycin limb as compared to 16% on the Methyl-CCNU arm (p = .39). Median survival for all treated patients was 43 weeks on both arms. Myelosuppression was found to be more significant on the Mitomycin-C arm. Regression analysis demonstrated that performance status, sex, and primary site were significant pretreatment characteristics for predicting survival. The response rates associated with this burdensome method of 5FU administration in combination with either Mitomycin-C or Methyl-CCNU appear to offer little advantage over bolus 5FU alone.

Adenocarcinoma↗
PubMed1978

Small-cell carcinoma of the lung: combined chemotherapy and radiation: a Southwest Oncology Group study.

Chemotherapy (doxorubicin, cyclophosphamide, and vincristine) was given in a sequential fashion with radiation of the primary tumor and brain to 358 patients with small-cell lung carcinoma (extensive disease in 250, limited in 108). Complete regression of tumor was obtained in 14% of patients with extensive disease and 41% of patients with limited disease, and complete or partial response in 57% and 75%, respectively. Median survival was 26 weeks for patients with extensive disease and 52 weeks for those with limited disease. Response duration was longer for patients in complete remission; one third had disease-free survival greater than 1 year. Toxicity from the combined treatment modalities was no greater than expected from the components given separately: fatal in 3.9%, and life-threatening but reversible in 8.4% of patients. Whole-brain radiation was effective in preventing isolated relapse at that site. This therapy appears both feasible and effective, with acceptable risks and some benefit to most patients.

Brain Neoplasms↗